NCT02137161View on ClinicalTrials.gov

Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery

PHASE4CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
CataractPseudoexfoliation Syndrome
Interventions
DRUG

Dexamethasone+Tobramycin eye drop

dexamethasone 0.1% and tobramycin 0.3% ophthalmic suspension

DRUG

Bromfenac eye drop

bromfenac ophthalmic solution 0.09%

Trial Locations (1)

42123

Arcispedale Santa Maria Nuova IRCSS - Ophthalmology, Reggio Emilia

All Listed Sponsors
lead

Azienda USL Reggio Emilia - IRCCS

OTHER_GOV

NCT02137161 - Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery | Biotech Hunter | Biotech Hunter